12:00 AM
Feb 26, 2007
 |  BioCentury  |  Strategy

Hybrigenics escape route

Proteomics company Hybrigenics S.A. last week said it divested two of its three discovery programs to focus on bringing ubiquitin-specific protease inhibitors into clinical development for cancer. The company will continue developing an in-licensed vitamin D analog for prostate cancer, which is in Phase I trials, but otherwise will focus its efforts entirely on USP inhibitors. The most advanced one is in preclinical testing for various cancers.

USPs are a family of enzymes that are attracting the interest of big pharma, said CEO Remi Delansorne. "Novartis recently published a patent on a USP, and we have had contact with two other big pharma companies that also are running early stage programs on USPs."

USPs are involved in...

Read the full 568 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >